Core Viewpoint - Four Seasons Pharmaceutical (00460) reported a significant increase in revenue and profitability for the first half of 2025, driven primarily by its aesthetic medicine business, which saw substantial growth due to strategic partnerships and successful marketing initiatives [1] Financial Performance - The company achieved a revenue of 1.146 billion RMB, representing a year-on-year increase of 20.69% [1] - Shareholder profit reached 103 million RMB, marking a turnaround from a loss to profitability [1] - A mid-term cash dividend of 0.99 cents per share is proposed [1] Business Segment Performance - Revenue from the aesthetic medicine segment amounted to approximately 585 million RMB, reflecting a year-on-year increase of about 81.3% [1] - The growth in the aesthetic medicine segment was attributed to enhanced strategic collaborations and the successful implementation of an upgraded marketing strategy [1] - The company made significant advancements in the regenerative field, with two self-developed injectable products receiving market approval [1]

Core Viewpoint - Four Seasons Pharmaceutical (00460) reported a significant increase in revenue and profit for the first half of 2025, driven primarily by its aesthetic medicine business, leading to a rise in stock price by over 4% [1] Financial Performance - Revenue for the first half of 2025 reached 1.146 billion RMB, representing a year-on-year increase of 20.69% [1] - Shareholder profit amounted to 103 million RMB, marking a turnaround from a loss to profit [1] - The company proposed an interim cash dividend of 0.99 cents per share [1] Business Segment Performance - The aesthetic medicine segment generated approximately 585 million RMB in revenue, reflecting a year-on-year increase of about 81.3% [1] - This growth was attributed to strategic partnerships and a successful marketing strategy upgrade for the company's aesthetic platform, Meiyan Space [1] - Meiyan Space achieved breakthroughs in the regenerative field with the approval of two self-developed injection products: polycaprolactone microsphere facial filler (referred to as "girl's needle") and polylactic acid facial filler (referred to as "youth needle") [1]

收益的变化，来自医美业务的收益约为人民币5.85亿元，同比上升约81.3%，主要由于期内本集团旗下 医美平台渼颜空间加大与多家医美机构的战略合作以及大力推广营销战略3.0版本升级取得显著成功， 产品获得市场的高度认可，从而推动医美销售收入大幅增长。 格隆汇8月29日丨四环医药(00460.HK)公告，截至2025年6月30日止6个月中期业绩，集团取得总收益约 为人民币11.46亿元，同比上升约20.7%。期内公司拥有人应占溢利约为人民币1.03亿元(截至2024年6月 30日止6个月：亏损人民币3340万元)，集团实现扭亏为盈，主要由于期内集团医美业务收益增加所致。 期内的每股基本盈利为人民币1.11分。由于公司成功完成了集团整体扭亏的阶段性战略目标，为感谢股 东及投资者的支持，董事会议决宣派期内中期现金股息每股人民币0.99分(相等于每股1.09港仙)。 ...

Core Insights - Four Seasons Pharmaceutical (00460) reported a mid-year performance for 2025, with revenue of 1.146 billion RMB, a year-on-year increase of 20.69% [1] - The company achieved a profit attributable to shareholders of 103 million RMB, recovering from a loss of 33.424 million RMB in the same period last year [1] - Basic earnings per share were 1.11 cents, and the company proposed an interim cash dividend of 0.99 cents per share [1] Revenue Growth - The increase in revenue was primarily driven by the medical aesthetics business, which generated approximately 585 million RMB, up about 81.3% from 323 million RMB in the same period of 2024 [1] - The significant growth in medical aesthetics sales was attributed to strategic partnerships and an upgraded marketing strategy for the company's medical aesthetics platform, Meiyan Space [1] R&D and Product Development - Innovation and product matrix enhancement are core competitive engines for Meiyan Space [2] - Meiyan Space has established five R&D platforms focusing on international innovative materials, regenerative materials, HA products, biopolymers, and composite innovative materials [2] - The company has a professional R&D team of over 80 members, advancing the development and registration of over 60 medical aesthetic products, covering categories such as injections, photonic devices, weight loss drugs, and skincare products [2] - Recent breakthroughs include the approval of two self-developed regenerative injection products: polycaprolactone microsphere facial filler (Youth Needle) and polylactic acid facial filler (Childlike Needle) [2]

Group 1 - The core viewpoint of the articles highlights the significant financial turnaround of the company, with a revenue of 1.146 billion RMB for the first half of 2025, representing a year-on-year increase of 20.69% [1] - The company reported a profit attributable to shareholders of 103 million RMB, compared to a loss of 33.424 million RMB in the same period last year, indicating a successful recovery [1] - The basic earnings per share were reported at 1.11 cents, and the company proposed an interim cash dividend of 0.99 cents per share [1] Group 2 - The increase in revenue is primarily driven by the aesthetic medicine business, which generated approximately 585 million RMB, up about 81.3% from 323 million RMB in the same period last year [1] - The growth in the aesthetic medicine segment is attributed to strategic collaborations with multiple aesthetic institutions and the successful implementation of an upgraded marketing strategy [1] - The company has established five major research and development platforms focusing on various innovative materials and products, enhancing its competitive edge in the market [2] - The R&D team, consisting of over 80 professionals, has advanced the development and registration of more than 60 aesthetic medicine products, covering a range of categories [2] - The company achieved breakthroughs in the regenerative field with the approval of two self-developed injection products, enhancing its product offerings [2]

EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 四環醫藥控股集團有限公司 | | 股份代號 | 00460 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月之中期現金股息 | | 公告日期 | 2025年8月29日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.0099 RMB | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.0109 HKD | | 匯率 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 截至二零二五年六月三十日止六個月 中期業績公告 四 環 醫 藥 控 股 集 團 有 限 公 司（「四環醫藥」或「本公司」）董 事（「董 事」）會（「董事會」） 欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月（「期 內」）的 未 經 審 核 綜 合 業 績 連 同 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 的 比 較 數 字。該 中 期 簡 明 綜 合 財 務 資 料 已 經 由 本 公 司 的 外 部 核 數 師 安 永 會 計師事務所根據國際審計和核證準則委員會頒佈的國際審閱業 ...

Core Viewpoint - The approval of the innovative ALK inhibitor, Dirocitinib (formerly known as "Dazatinib"), by the National Medical Products Administration (NMPA) in China marks a significant advancement for the company in the oncology field, particularly for the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) [1][2]. Group 1: Product Approval and Significance - The product is the third class 1 innovative drug approved for the company and the second innovative oncology drug, showcasing the company's continuous progress in targeted therapies from breast cancer to lung cancer [1]. - Dirocitinib has four core advantages: rapid onset of action, superior tumor suppression, prolonged relief for patients, and significant survival benefits, achieving the goal of chronic disease management [1]. Group 2: Clinical Breakthroughs - Dirocitinib successfully addresses clinical challenges by controlling brain metastases and ensuring safety, effectively penetrating the blood-brain barrier [2]. - The safety profile of Dirocitinib shows significant advantages, with adverse reactions primarily being mild gastrointestinal issues, which can be managed through symptomatic treatment or dose adjustments [2].

Core Viewpoint - The approval of the innovative ALK inhibitor drug, Dirocitinib (formerly known as "Dahisitinib"), by the National Medical Products Administration (NMPA) in China marks a significant advancement for the company in the oncology field, particularly for treating ALK-positive advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Product Approval and Significance - The drug Dirocitinib is the third innovative drug approved for market by the company's subsidiary, Xuan Zhu Bio-Tech, and the second innovative oncology drug, showcasing the company's continuous progress in targeted therapies from breast cancer to lung cancer [1] - Dirocitinib has four core advantages: rapid onset of action, superior tumor suppression, prolonged relief for patients, and significant survival benefits, achieving the goal of chronic disease management [1] Group 2: Clinical Breakthroughs - Dirocitinib successfully addresses clinical challenges by controlling brain metastases and ensuring safety, effectively penetrating the blood-brain barrier and compensating for existing therapies' shortcomings in central nervous system protection [2] - The drug demonstrates significant safety advantages, with adverse reactions primarily being mild gastrointestinal issues, which can be managed through symptomatic treatment or dose adjustments, leading to improved long-term medication adherence among patients [2]

Core Viewpoint - The approval of the innovative ALK inhibitor, Dirocitinib (formerly known as "Dahitinib"), by the National Medical Products Administration (NMPA) in China marks a significant milestone for Xuan Bamboo Biotechnology and provides a breakthrough treatment option for patients with ALK-positive advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Product Approval and Significance - Dirocitinib is the third innovative drug approved for Xuan Bamboo Biotechnology and the second innovative oncology drug, showcasing the company's continuous advancement in targeted therapies from breast cancer to lung cancer [1] - The approval represents an important research and development milestone for Xuan Bamboo's innovative drug pipeline, contributing to the acceleration of cancer prevention and treatment goals under the "Healthy China 2030" initiative [2] Group 2: Drug Advantages - Dirocitinib has four core advantages: rapid onset of action, superior tumor suppression, prolonged relief for patients, and significant survival benefits, achieving the goal of chronic disease management [1] - The drug effectively penetrates the blood-brain barrier, addressing existing therapies' shortcomings in central nervous system protection, while demonstrating a favorable safety profile with manageable side effects [2] Group 3: Clinical Impact - In pivotal Phase III clinical trials, Dirocitinib showed significant efficacy compared to existing first- and second-generation ALK inhibitors, particularly against resistant mutations such as G1202R and I1171N [1] - The drug's safety profile includes primarily mild gastrointestinal reactions, with reduced risks of pleural effusion and hepatotoxicity, enhancing long-term medication adherence among patients [2]